Michael Schotsaert News Today

/PRNewswire/ -- In some patients, infection with the pandemic virus SARS-CoV-2 can trigger a dangerous immune response in hardened fatty deposits (plaques)...

The RNA adjuvant triggers antiviral pathways inside the cell

While much of the global concern has subsided, COVID-19 is still a very real threat, especially to people with compromised immune systems or who are over 65.

While vaccines are known to offer protection against serious illness and death, vaccines can be improved in their ability to stop the spread of SARS-CoV-2 at the point of entry in the upper respiratory tract, the research led by the University of Michigan (U-M) and the Icahn School of Medicine at Mount Sinai, US, said

A collaborative research effort led by the University of Michigan and the Icahn School of Medicine at Mount Sinai has resulted in a nasal vaccine adjuvant that stops COVID infection in both young and old mice.

Faculty from the Departments of Microbiology, Medicine Genetics and Genomic Sciences, and Pathology and Molecular Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai play key roles in a National Institutes of Health (NIH) program set up to provide a real-time risk assessment of variants of SARS-CoV-2, the virus that causes COVID-19. The program, called SARS-CoV-2 Assessment of Viral Evolution (SAVE) and described in a paper published March 31 in Nature, assesses how the variants m...

Program employs a coordinated approach and serves as a template for response against rapidly evolving pandemic pathogens